PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'CHU and Inserm, Poitiers, 1402 CIC, France.\', \'Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.\', \'Amgen Inc, Thousand Oaks, USA.\', \'Levine Cancer Institute/Atrium Health, Charlotte, NC, USA.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1080/17474086.2021.1955343
?:hasPublicationType
?:journal
  • Expert review of hematology
is ?:pmid of
?:pmid
?:pmid
  • 34546844
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 0.852
?:rankingScore_hIndex
  • 27
is ?:relation_isRelatedTo_publication of
?:title
  • A combination of carfilzomib, dexamethasone, and daratumumab for treatment of adult patients with relapsed/refractory multiple myeloma in two dosing regimens: once-weekly and twice-weekly.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all